{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-035995","form_type":"8-K","ticker":"RNXT","cik":"0001574094","company_name":"RenovoRx, Inc.","filed_at":"2026-08-04T20:10:21+00:00","discovered_at":"2026-08-04T20:12:00.309564+00:00","generated_at":"2026-08-04T20:12:31.680534+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"RenovoRx to highlight TAMP platform at JonesTrading KOL webinar on Aug 13, 2026","bullets":["RenovoRx to participate in JonesTrading KOL webinar on pancreatic cancer on Aug 13, 2026 at 1:30 p.m. ET.","RenovoCath sales of ~$1.1M in 2025 and record $563K in Q1 2026.","Full enrollment in Phase III TIGeR-PaC trial expected very near term; final data readout mid to late 2027.","IAG (intra-arterial gemcitabine via RenovoCath) has Orphan Drug Designation for pancreatic and bile duct cancer."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-035995","json":"https://secwatch.observer/filing/0001493152-26-035995.json","markdown":"https://secwatch.observer/filing/0001493152-26-035995.md","text":"https://secwatch.observer/filing/0001493152-26-035995.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1574094/000149315226035995/0001493152-26-035995-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1574094/000149315226035995/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-04T20:12:31.680534+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}